In short
Polymyalgia rheumatica is an inflammatory condition that causes muscle pain and stiffness, mainly affecting the shoulders, neck, and hips. While the exact cause remains unknown, effective treatment options exist to help patients manage symptoms and return to their daily activities. Understanding both standard approaches and emerging therapies can help patients and their doctors make informed decisions about care.
Key points
- Polymyalgia rheumatica primarily affects people over 50, with most cases occurring in those over 65, and the condition is more common in women than men
- Prednisolone is the main treatment and can produce dramatic improvement within days, though treatment typically continues for 12 months to 2 years
- The FDA recently approved sarilumab, a biologic medication, offering a new option for patients who struggle with long-term steroid side effects
- Regular monitoring through blood tests and follow-up appointments is essential to ensure treatment is working and to watch for side effects
- About 10-20% of polymyalgia rheumatica patients may develop giant cell arteritis, a serious condition requiring immediate medical attention
- Long-term steroid use can cause side effects including weight gain, high blood pressure, bone weakening, and increased infection risk
- Methotrexate or hydroxychloroquine may be added to treatment for patients with frequent relapses or steroid intolerance
- Clinical trials continue to explore new treatments targeting specific inflammatory pathways, offering hope for better therapies with fewer side effects in the future
How Treatment Helps People with Polymyalgia Rheumatica
The main goal of treating polymyalgia rheumatica is to relieve pain and stiffness so that patients can return to normal activities. Without treatment, this condition can make it extremely difficult to perform everyday tasks like getting dressed, brushing hair, or getting out of bed in the morning. The aches can be so severe that they interfere with sleep and prevent people from lifting their arms above their shoulders.
Treatment approaches depend on several factors, including how severe the symptoms are, how long they have been present, and whether the patient has any other health conditions. The intensity of morning stiffness, which typically lasts longer than 45 minutes, is an important factor doctors consider when planning treatment. Age also plays a role, as polymyalgia rheumatica primarily affects people over 50, with most diagnosed individuals being over 65 years old.
Medical societies and healthcare organizations have developed guidelines to help doctors choose the most appropriate treatments. These recommendations are based on years of research and clinical experience. At the same time, researchers continue to explore new therapies through clinical trials, hoping to find treatments that work better or cause fewer side effects than current options.
Standard Treatment Approaches
The cornerstone of polymyalgia rheumatica treatment is a type of medication called corticosteroids, specifically a drug named prednisolone (also known as prednisone in some countries). This medication works by blocking certain chemicals in the body that cause inflammation, thereby reducing pain and stiffness.
When doctors first prescribe prednisolone for polymyalgia rheumatica, they typically start with a moderate dose, often between 10 and 15 milligrams per day taken as tablets. The response to this treatment can be quite dramatic—many patients notice significant improvement within just a few days, and some even feel better after the first dose. However, the speed of response can vary, and it may take two to three weeks for some patients to experience full relief.
The treatment duration for polymyalgia rheumatica is typically long. Most people need to continue taking prednisolone for about 12 months to 2 years to prevent symptoms from returning. The dose is usually reduced gradually every one to two months if the patient is responding well and symptoms remain under control. This slow tapering is important because suddenly stopping steroid medication can make a person very unwell.
While prednisolone is highly effective at controlling symptoms, it can cause side effects, especially with long-term use. Common side effects include increased appetite leading to weight gain, high blood pressure, and weakening of the bones, a condition known as osteoporosis. Some patients also develop stomach ulcers or an increased risk of infections, particularly from the varicella-zoster virus that causes chickenpox and shingles.
To monitor how well treatment is working and watch for side effects, patients need regular follow-up appointments. During these visits, doctors check how symptoms are responding, whether the medication dose needs adjustment, and how well patients are coping with any side effects. Blood tests may be performed to measure inflammation levels in the body. Follow-up appointments are typically scheduled every few weeks during the first three months of treatment, then at least every three months during the first year.
In some cases, doctors may recommend additional medications alongside prednisolone. Immunosuppressant medicines like methotrexate may be prescribed for patients who experience frequent relapses (return of symptoms) or don't respond well to standard steroid treatment. Methotrexate works by suppressing the immune system, which is the body's defense against infection and illness. This can help some patients reduce their dose of prednisolone or prevent symptoms from coming back.
Another medication sometimes used is hydroxychloroquine, particularly for patients who have problems with long-term steroid use due to side effects. Pain relievers such as paracetamol may also be recommended to help relieve pain and stiffness while the prednisolone dose is being reduced.
It's worth noting that common over-the-counter pain medications called nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen (sold as Advil or Motrin) or naproxen sodium (sold as Aleve), are generally not effective for treating polymyalgia rheumatica.
Patients taking steroids for longer than three weeks or at high doses should be given a steroid card by their doctor or pharmacist. This card explains that the person regularly takes steroids and that the dose should not be stopped suddenly. Patients should carry this card with them at all times.
Emerging Treatments Being Studied in Clinical Trials
While corticosteroids remain the standard treatment, researchers continue to explore new approaches that might work better or cause fewer side effects. One promising development in the treatment of polymyalgia rheumatica involves medications called biologics.
Recently, the Food and Drug Administration approved a biologic medication called sarilumab for treating polymyalgia rheumatica. This represents an important advancement because it offers an alternative for patients who have trouble with long-term steroid use due to problematic side effects. Sarilumab is a type of biologic that works differently from traditional steroids, targeting specific parts of the immune system that contribute to inflammation.
The approval of sarilumab came after clinical trials showed it could help control symptoms in patients with polymyalgia rheumatica. These trials evaluated how well the medication worked compared to standard treatment and monitored patients for any safety concerns. The studies progressed through different phases: Phase I trials focused on safety, Phase II trials examined whether the treatment was effective, and Phase III trials compared the new treatment directly with standard approaches.
Clinical trials for polymyalgia rheumatica often include patients who have been diagnosed with the condition and are experiencing typical symptoms like widespread muscle pain and stiffness, particularly in the shoulders and hips. Many trials look for participants who have elevated markers of inflammation in their blood, such as high levels of erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). These blood tests help confirm that inflammation is present in the body.
Some clinical trials investigate whether combining different medications might help patients reduce their steroid doses or prevent relapses more effectively. For example, studies have examined whether adding methotrexate or other immunosuppressant drugs to standard prednisolone treatment can allow patients to use lower doses of steroids while still controlling symptoms. This is important because lower steroid doses typically mean fewer side effects over time.
Research studies are also exploring the underlying causes of polymyalgia rheumatica to develop more targeted treatments. Scientists have identified certain genetic factors that may make people more susceptible to the condition. For instance, variations in genes called HLA-DRB1*04 appear more frequently in people with polymyalgia rheumatica, occurring in up to 67% of cases. Understanding these genetic connections helps researchers design treatments that address specific biological pathways involved in the disease.
Other research has focused on genetic variations affecting proteins involved in inflammation, such as ICAM-1, RANTES, and IL-1 receptors. These proteins play roles in how the immune system responds and causes inflammation. By understanding these mechanisms better, scientists hope to develop medications that can more precisely target the inflammation without affecting other parts of the immune system.
Clinical trials for polymyalgia rheumatica take place in various locations around the world, including the United States, Europe, and other regions. Patients interested in participating in clinical trials can discuss this option with their rheumatologist or healthcare provider, who can help determine whether any appropriate studies are available and whether the patient meets the eligibility criteria.
Preliminary results from various studies have shown that some of these newer approaches can help reduce inflammation markers in the blood, improve patient-reported symptoms, and maintain positive safety profiles. However, researchers continue to monitor long-term outcomes to ensure these treatments remain safe and effective over extended periods.
Most common treatment methods
- Corticosteroid therapy
- Prednisolone is the main medication, typically starting at 10-15 mg per day
- Treatment usually lasts 12 months to 2 years with gradual dose reduction
- Symptoms often improve within a few days, sometimes after the first dose
- Regular follow-up appointments are needed to monitor response and side effects
- Immunosuppressant medications
- Methotrexate may be added for patients with frequent relapses
- Hydroxychloroquine can be used when long-term steroid side effects are problematic
- These medications work by suppressing the immune system
- They may help reduce the needed dose of steroids
- Biologic therapy
- Sarilumab was recently approved by the FDA for polymyalgia rheumatica
- This medication targets specific parts of the immune system
- It provides an alternative for patients who cannot tolerate long-term steroids
- Clinical trials showed effectiveness in controlling symptoms
- Supportive care
- Paracetamol may be recommended for pain relief while reducing steroid doses
- Regular blood tests monitor inflammation levels (ESR and CRP)
- Osteoporosis medications may be prescribed to prevent bone loss from steroids
- NSAIDs like ibuprofen are generally not effective for polymyalgia rheumatica
